Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea
- PMID: 3558723
- DOI: 10.1210/jcem-64-5-1021
Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea
Abstract
To determine whether women with PRL-secreting pituitary tumors have similar decreases in cortical and trabecular bone and to determine whether bone loss associated with hyperprolactinemia is reversible, we measured forearm and vertebral bone mineral in normal women and in amenorrheic women with treated and untreated hyperprolactinemia. The mean spinal bone mineral content in hyperprolactinemic women [130 +/- 23 (+/- SD) mg/mL] was 25% lower than that in normal women (167 +/- 28 mg/mL), while the mean forearm bone mineral content (0.71 +/- 0.04 g/cm2) was similar to that in normal women (0.73 +/- 0.05 g/cm2). Women with normal serum PRL levels and regular menses after transsphenoidal surgery had slightly higher mean spinal bone mineral content (149 +/- 28 mg/mL) than women who remained amenorrheic after surgery (129 +/- 19 mg/mL), but the mean value in the cured women remained significantly lower than that in normal women. In contrast, women who had undergone successful transsphenoidal pituitary surgery had mean forearm bone mineral comparable to that in normal women. There was no correlation between vertebral and radial bone mineral in hyperprolactinemic women and no correlation between bone mineral and serum PRL, serum estradiol, or duration of amenorrhea when age was taken into account. These findings suggest that hyperprolactinemia and/or decreased gonadal function in women with PRL-secreting pituitary tumors are associated with more prominent effects on trabecular bone in the spine than on cortical bone in the wrist. In addition, the abnormal spinal bone mineral content after successful treatment suggest that normalization of estradiol and PRL secretion is not sufficient to restore bone mineral content to normal, although it may be stabilized.
Similar articles
-
Bone density in amenorrheic women with and without hyperprolactinemia.J Clin Endocrinol Metab. 1983 Jun;56(6):1120-3. doi: 10.1210/jcem-56-6-1120. J Clin Endocrinol Metab. 1983. PMID: 6404918
-
Effects of prolactin and estrogen deficiency in amenorrheic bone loss.J Clin Endocrinol Metab. 1988 Jul;67(1):124-30. doi: 10.1210/jcem-67-1-124. J Clin Endocrinol Metab. 1988. PMID: 3379129
-
A longitudinal analysis of premenopausal bone loss in healthy women and women with hyperprolactinemia.J Clin Endocrinol Metab. 1992 Sep;75(3):698-703. doi: 10.1210/jcem.75.3.1517357. J Clin Endocrinol Metab. 1992. PMID: 1517357
-
The effects of hyperprolactinemia on bone and fat.Pituitary. 2009;12(2):96-104. doi: 10.1007/s11102-008-0097-3. Pituitary. 2009. PMID: 18338266 Review.
-
Bone loss in amenorrheic athletes.Nutr Rev. 1986 Nov;44(11):361-3. doi: 10.1111/j.1753-4887.1986.tb07572.x. Nutr Rev. 1986. PMID: 3540740 Review. No abstract available.
Cited by
-
Prevalence of osteopenia in men with prolactinoma.J Endocrinol Invest. 2005 Jan;28(1):12-7. doi: 10.1007/BF03345523. J Endocrinol Invest. 2005. PMID: 15816365
-
Osteocalcin levels in patients with microprolactinoma before and during medical treatment.J Endocrinol Invest. 1990 May;13(5):419-22. doi: 10.1007/BF03350694. J Endocrinol Invest. 1990. PMID: 1974270
-
Hyperprolactinemia.J Hum Reprod Sci. 2013 Jul;6(3):168-75. doi: 10.4103/0974-1208.121400. J Hum Reprod Sci. 2013. PMID: 24347930 Free PMC article. Review.
-
Bone mineral density in hyperandrogenic amenorrhoea.Calcif Tissue Int. 1993 Jun;52(6):422-4. doi: 10.1007/BF00571330. Calcif Tissue Int. 1993. PMID: 8369988
-
Skeletal fragility in pituitary disease: how can we predict fracture risk?Pituitary. 2024 Dec;27(6):789-801. doi: 10.1007/s11102-024-01447-3. Epub 2024 Sep 6. Pituitary. 2024. PMID: 39240510 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical